Hemab Therapeutics Holdings, Inc. (COAG) fair value analysis
Nasdaq · Updated 2026-10-19
COAG price how computed
Valuation status
No fair-value estimate yetCOAG has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for COAG yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $30.07
- Sector
- Healthcare
- 12-month range
- $27.13–$45.00
- Market cap
- $1.4B
- From 52-week high
- -33.2%
- Shares outstanding
- 46.7M
- Rank in Healthcare by quality score
- #231 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Hemab Therapeutics Holdings, Inc. is a biopharmaceutical company that focuses on developing and commercializing therapies for rare bleeding and clotting disorders. The company operates primarily in the United States and serves patients with conditions related to hemostasis and thrombosis.
COAG currently ranks #231 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.4B
- Debt / equity
- 0.00
- Shares outstanding
- 46.7M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 30 · oversold
Earnings how computed
- Next earnings report
- 2026-11-10
- Last 1 quarters vs consensus
- 0 beat, 1 missed
- Quarter by quarter
- 2026-06 ▼ miss (-27.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $62.7
- Target vs last price
- +108.5%
What our data shows for COAG
- Shares are trading in the lower third of their 12-month price range of $27.13–$45.00.
- The 14-day relative strength index sits at an oversold 30.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- COAG's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the COAG conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — COAG's Relative Strength Index moved into oversold territory this week, shifting from a neutral zone in the prior period. This technical indicator suggests the stock has experienced selling pressure that may be approaching an extreme level. The stock's valuation assessment remains pending a complete evaluation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for COAG showed movement this week as the relative strength index transitioned from oversold territory into neutral zone. The healthcare sector stock's current valuation verdict remains under review as full valuation assessment is being awaited. This shift in the RSI indicator suggests a change in the stock's momentum dynamics from last week's oversold condition.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is COAG stock undervalued?
TickrTrends has no fair-value estimate for COAG yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is COAG's TickrTrends verdict?
COAG is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does COAG compare to other Healthcare stocks?
COAG ranks #231 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is COAG overbought or oversold?
COAG's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does COAG report earnings next?
COAG's next earnings report is scheduled for 2026-11-10, per the published earnings calendar.
Does COAG usually beat earnings estimates?
Over its last 1 reported quarters COAG beat the consensus estimate 0 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about COAG?
Of 5 analysts covering COAG, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $62.7 (+108.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.